my TSH moved and I cannot work out whether ACHIEVE is why
my TSH moved and I cannot work out whether ACHIEVE is why — a position I have arrived at slowly and would like tested. What is actually known, and what is being assumed. Known: it is a small-molecule GLP-1 receptor agonist, dosed daily, with clinical programmes reporting in both obesity and type 2 diabetes. Its…
Agreed that phase 3 is where the comparison becomes fair. Everything before it is inference.
ATTAIN and ACHIEVE are the programmes to keep straight
The no-timing-restriction thing is the part I would care about most in practice, and it barely gets mentioned here.
The no-timing-restriction thing is the part I would care about most in practice, and it barely gets mentioned here.
Disagreeing with this bit: daily dosing is a different adherence problem, not a better one.
Daily rather than weekly sounds trivial until you think about what a missed dose means in each case.
Milligram comparisons across molecule classes are meaningless. Potency is a property of the molecule at its receptor, not of the number on the label.
Disagree. You are comparing doses across a small molecule and a peptide, which is not a comparison of anything.
Which programme and which readout are you quoting?
the manufacturing story is genuinely different from the injectables